Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bad analogy. I more fitting anology would be a public bus. The riders do not have a say in direction of bus. They can pull the chain and get off. They have once a year chance to vote at the ASM like a yearly Transit Authority meeting. It is a bit of a rough ride for some so they complain or get off. But their complaints are just noise and irritation maybe designed to get others to get off the bus or sell their stock.
This opens up a possibility that the spinoff company could be sold to a BP that would take over distribution and trigger the milestone payment to CYDY and ramp sales quickly. That way Veyra can remain independent. (I likely mis spelled the company name)
Brilliant Logic Doc.
It takes a tremendous amount of calculations and logic for a Company to dare to go where none have gone before. Investors likewise must rely on logic rather than emotion if they wish to ride along with said visionary Company to the very frontier of science and medicine. Where NWBO is determined to go in treatment of brain cancer is the unknown and uncharted frontier of medical science.
With Dr.LL as navigator and LP as captain I am willing to go along for the ride and not continually question the caculations of the navigator or the decisions of the captain. To do so would be illogical in the extreme to the point of hysteria.
As retail investors we can relax and enjoy the ride and share in the possible astonishing achievements or we can simply exit the vessel.
For me there is no better view to the future of cancer treatment (and sharing in a possible explosion in Market Cap ) than front row on NWBO.
Major buys hitting the tape. 105k and 160k @.71 and some smaller 20ks oops and another 105k. Smart traders are buying here or shorts are covering. Not likely to go lower at least for today.
I agree with Bucwheat. This looks like machinations of the Market Makers. Earnings are due anyway and they could be front running that or shorting short term on the good news thinking might not be another catalyst for awhile. Daily RSI is 25% that condition rarely last more than 10 trading days and is usually followed by a big surge in share price in the weeks following a break back up over RSI 30%. The last time it CYDY stock price broke back over RSI 30% CYDY jumped from $1.05 to $1.37 in five trading days. This time the RSI dip is deeper so could see a quicker and higher rebound. RSI 24% is a good time to buy in most instances. It could go lower but could also rebound sharply at any moment. If naked shorting it could rebound before the end of the day today. I am definitely a buyer here and selling some blue chips to amass shares of CYDY.
Very true and especially if one believes the true market value if traded on AMEX or NASDQ should be in the $3-7 billion market cap range of peers in the preapproval perevenue biotech space just on current development stage NWBO is at now. Solid DD is key. NWBO is a battleground stock and price suppression has been applied for many years. When that situation reverses one might be shocked how fast and how high the price can rise unless one has experienced that before. The examples are many of biotechs in that market cap range with a fraction of both the potential and probabilities of reaching that potential as compared with NWBO.
That is correct. And while the subgroup analysis can not support a EUA it is exploratory and illuminates a path forward to a Phase 3 registration trial using that subgroup as the target group to test in the controlled trial. This is what was done the FDA is on board with it and the FDA even stated they would be open to that in the "Hit Letter" which was not a hit letter in fact it was simply statement of the FDA current analysis of the trial status and more to cover FDA azzes than to hit out at CYDY. No other company has made it to Phase 3 in this population therefore the fact that CYDY is right there at Phase 3 makes CYDY geometrically more valuable. The current market cap of CYDY is grossly undervalued by the Market. One can take that to the Bank. I will definitely take it to the Bank in a Big Big way!
Or NWBO price flashes over 5x or10x overnight and they find them priced out of the investment of the decade.
Yes the first most manipulated stocks. The second was Anavex that went from $1.26 to $30 in 18 months.just last year. The basher cry was fire the CEO of Anavex. AVXL still does not have approval or phase 3 readout but now sits at $18.
CytoDyn is more disruptive and much more potential. CYDY is possibly a similar 20x bagger in 18 to 24 months.
No like juggling "Wet" dynamite where the nitro has sweated out of the stick onto the surface.
A former AF worst biotech CEO was CEO of Arrowhead right before ARWR went from $3 to $70 plus just a few years ago within 18 months. Eighteen months and CytoDyn may be $25 plus.
Agreed. Denzel is capable of delivering a compelling unifying speach. Unfortunately he is too smart and incorruptible to stand for public office.
If Denzel Washington was President of USA Cofer Black would be Secretary of State. Denzel recognises talent.
But of course the Revolution will not be televised.
Denzel for President 2024. Game on! Ha ha
Of course. Late in year can always find bargans in pre revenue companies. Naturally if one does not have convction in the prospects of the company then no price is a good price.
I have a strong convicion in the prospects of Outlook. So do other market participants. The offer due to demand was increased 500%and was an all bought deal. Likely they could have increased it more.
Not to confuse anyone with details the USA ADRs represent 30 ordinary TASA shares. So if one buys 1000 USA shares same as 30000 TASA ordinary shares. 660 million ordinary shares currently =22 million ADRs. Fully diluted with warrants and options are 880 MM ordinary =29.33 ADRs and that is all there is period. A conservative USA $5 billion market cap when CANF technologies are appreciated by the market yield a pps of $170. Each $1 bill =$34 pps. Madrigal on NASH promise with no approvals rose from $18 in Sept 2017 to $300 plus by June 2018 just 9 months. 16 bagger on just promise. We got similar 20 bagger in Anavex Life Sciences from $1.26 in Dec 2018 to $30 a short 18 months later. Again no approvals or even trial readouts in its monster indication ALZ just change in sentiment and excitement. AVXL is still holding $18.
Can-fite has similarly monster indications and more of them than MDGL or AVXL.
Thanks for all your informative posts Midas. I have been holding a starter position for a few years. Now I see a great risk reward for a near term catalyst. Price point has wrung a lot of risk out of this so the equation is heavy to the reward side. Adding at about 1/2 price of my starter position. Remember the hoopla regarding Madrigal and it's NASH drug. One NDA and CANF could see the kind of market cap appriecation we enjoyed with Madrigal. Come sing for us Can-Fite
Eleven days after that Dr Lazari tweet on Aug 12, 2021 CytoDyn filed an SEC document to register shares for sale to the public. There after in due course the SEC declared that filing EFFECTIVE! In other words the SEC allowed the sale of CytoDyn stock to the public. Would the SEC do that if they were currently (or ever were) investigating CytoDyn. Of course not that would be an illegal act by the SEC not doing what they are chartered to do.
This is confirmation that the SEC was NOT investigating CytoDyn. It is plane as day in the SEC filings why must I continually have to point this out?
Dr Linda Lui just a few days ago was been appoint to Clearpoint Neuro Board of Directors so it seems more than Scientific advising. Maybe to cement some ties for business development with new customers of its brain surgery navigation tools.
NWBO currently meets all the requirements of NYSE American exchange except the minimum share price of $2 or $3. It is a streamlined process and low fee of around $75k to join. A 1 for 4 split would give NWBO a lot of headroom in the available shares to offer in public or private offerings and would meet the minimum price for up listing. It could be done simultaneously overnight in a surprise move. The only draw back is that it would give short sellers more room in their margin accounts as $2.50 is per share margin requirement held for each share held short. However if there is a significant amount of shares held short one might deduce that these are in accounts valued at more than $25 million and therefore exempt from the $2.50 cash margin per share requirement for shares held short. This of course would only make sense to do simultaneously or shortly after a very good catalyst that would create a great demand for shares of the up listing company. Nasdaq up list would require $20 million shareholder equity in addition to minimum share price, not sure NWBO has that but they would qualify for NYSE American without that. Currently just need one more item to qualify that is the minimum share price. I hope that answers your question.
NWBO could get quite interesting over the next few months.
Speaking of up listing it might be a good move to up list simultaneouly with TLD and Journal publication. In a surprise overnight move.
On approval of CYDY BLA the stock price will go BALLISTIC!
Two more CytoDyn ballistic missiles were also launched yesterday in the two peer review submissions. Six months from now one or both might be approved and published causing more explosions in the upward value of CytoDyn.
Time to buy more Cyto-RocketDyn!
Wow! Excellent news that CYDY will be able to ditch Chiral. CYDY ditched
Amarex that was great. Moving on and moving up! BLA on track. Maybe 12 months to massive revenues.
Regulus checks all the boxes for patient long term pre-revenue biotech growth/value investors. It also looks like a timely time to buy. A year out from catalysts and more than two years cash runway. Buy low and just wait for the forest to grow.
Is this pull back to 0.97 the pause the refreshes the continuation of the breakout? First chance today to buy on the bid.
Breakout!
It possibly means uplist to big board exchange like AMEX before TLD.
Boom! News out about final financing before TLD for $15 million 22 mo. Loan no payments for 8 mo. Then 8%. Can be exchanged for shares after first stock sales after TLD. TLD coming soon!
The SEC filings show conclusively that CYDY is not the subject of an SEC investigation or any other investigation that the SEC is aware of. October 19, 2021 five weeks ago the SEC filed a Notice of Effectiveness for a stock registration Form S-3 filed by CYDY on August 19, 2021. The SEC would not and could not have declared the Effectiveness of the August 19, 2021 Form S-3 Stock Registration Statement filed by CYDY. It is right there in black and white official SEC documents. The SEC could not have done this unless there was never this investigation of CYDY or CYDY had been cleared of any wrong doing or false statements.
This position is completely false and anyone has to do to know that the SEC is NOT investigating CYDY or the institutions involved with the PIPEs is read the SEC filings. If the SEC was investigating the SEC could not by law declare the Form S-3 filed by CYDY on August 19, 2021 as effective. The SEC filed Notice of Effectiveness in October 2021. This is very basic.
If one's full time endeavor is attempting to influence opinion or sentiment on a message board and other social media either positive or negative one can make themselves appear like an expert.
NWBO is in 5th overtime just need a two point conversion to WIN BIG. Point one TLD point two Journal publication. It is coming. Don't blink!
What investors need to understand is that trials take time and money. CytoDyn needed more cash to speed up the trials. With the newly authorized shares and stock sales they have money now so can move things forward faster. BP can still move its trials faster because they have more money and can pay the MDs and PIs more. One can invest in BPs if one desires faster trials although that is a much lower risk/reward equation. But BP is a safer more steady investment that pays dividends typically. If one wants the big bang then one has to accept the risk. If one does not want to accept the risk do not invest in pre-revenue biotech but please do not come crying about it.
CYTODYN WAS NEVER THE TARGET OF THE INVESTIGATION. Do you read the SEC filing document that you think says that "CytoDyn is under investigation "? Because that is NOT what it says. It says CytoDyn was served Subpoenas in an investigation. No information on who was being investigated. The statements that clearly must confuse you and others is the SEC required statement written by CytoDyn securities lawyers that Management do not know if there will be any liability on the company or not. CytoDyn management likely has a good idea of what is being investigated by what the FBI subpoena asked for but by law they can not disclose as it would jeopardize an ongoing investigation.
What "WE" and by "WE" I mean those of us the actually read the SEC filings and have the experience to comprehend them near certainly KNOW is that CytoDyn is NOT the target of the investigation as the SEC subsequently ruled a CytoDyn Prospectus as effective and issued a S-3. Even newbie or casual investors should know that the SEC would not allow a Company to sell stock when they are under investigation.
The 13D group clearly does not understand the ramifications of the "Investigation" and repeat over and over that it is a SEC Investigation of NP and CytoDyn. They want long investors to think that and likely fooled only themselves as there would be no escape for them from the alternative as it is a FBI criminal investigation of stock manipulation by outsiders. The Investigation is likely in dragnet phase of a criminal stock manipulation scheme which resulted in June 30, 2020 dump but continued through the 13D failed proxy fight. This FBI/DOJ Investigation is ripe for all encompassing multiple count indictments of the criminals involved, which are NOT NP or any managers or BOD of CytoDyn but might include those formerly of CYDY.
Check your figures. Fisrt approval should value NWBO in the $20-30 billion range. It should be a 10x bagger before approval. Been in stocks trading less than $200 million market cap and made the mistake of selling at only a 10x 1000% gain as they were on the way to 40x. One of those stocks Arrowhead yesterday licenced one of there minor early stage drugs in a $1 billion deal. Market cap $7 billion and just have one minor drug approved. ARWR moved from $1 -2 sp range to $17-20 in less than a year where I sold then in 18 months moved to $70+ . That is just one example. NWBO can and should move like that after they move to a major exchange. NWBO if successful should be valued $20-50 billion. This is especially true as they are managing and reduceing execution risks parallel with the regulatory advances. NWBO is so confident that they are working on vertical integration before approval.
NWBO much larger near term potential than ARWR in a more narrow indication but they are working on vertical integration in large scale manufacturing.
I see NWBO approaching multiple parabolic moves as ARWR did over the past 5 years. AVXL is another example. 14 cents to $30 now $18 in just a few years.
When NWBO is a 10x or 20x bagger from here it will just be the start of the run to a 50x-100x bagger. Time and uplist will get NWBO very valuable. Make no mistake NWBO true value right now before TLD should be $3-4 billion. With great date 10x that. Commercial success in time might gain another 5x-10x in market cap plus dividends potentially.
The data is a lock. The results of the trial are a near lock. When the Sawston facility is certified manufacturing will be a lock. Demand for the drug will be a lock. Expansion trials into other solid tumors will come near certainly so future growth prospects are a lock. There maybe only 5 biotech stocks with this amount of potential and two are on OTC. None other than NWBO is a near lock to be a success. Eighteen months a modest number is shares and uplist nets $million in capital gains for the patient investor.
BLA once filed should have PDUFA set six months or less out.
Nothing at all is up with that. Most all shares of any public company are held it Street Name which means in the name of their broker. The public list is of shareholders that had their shared registers in their own name which is usually Insiders, 5%+ owners and Institutions. He could have gotten personal voluntary disclosures from some dupees of his disgruntled shareholders but that info would be inherently unreliable.
Currently there is no TREATMENT AT ALL FOR NASH other than LIVER TRANSPLANT. SO NO SOC hence Accerated approval. Arrowhead made a 1 billion partnership agreement for ARWR early clinical stage candidate.
OTLK increased the offering size by 500% due to demand. I would say the offer was well received indeed. Now OTLK has a fairly comfortable cash runway. Cash problems averted.
Absolutely! Is a Chinese life worth less than an American life or European or Brazilian? Medicine is not about geopolitics or competition for profits. Only BP and the other Pigs of the Corona War would take profits over the the benefits to all humans. Such a move by Nader and CytoDyn together with the incrediblely compasionate responses to patients needing Leronlimab shows that Nader and CytoDyn value human life and demonstrates the fundamental core values of CytoDyn.
Bring Leronlimab forward for the benefit of all mankind.